<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medications used for targeted therapy in pediatric patients with pulmonary hypertension</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medications used for targeted therapy in pediatric patients with pulmonary hypertension</h1>
<div class="graphic"><div class="figure"><div class="ttl">Medications used for targeted therapy in pediatric patients with pulmonary hypertension</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="12.5%"></colgroup><colgroup span="3" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">US brand name</td> <td class="subtitle1">Dose/route</td> <td class="subtitle1">Side effects</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="5">PDE5 inhibitors</td> </tr> <tr> <td class="indent1">Sildenafil</td> <td>Revatio</td> <td> Age &lt;1 year: <ul class="decimal_heading"> <li>0.5 to 1 mg/kg per dose orally 3 times per day</li> </ul> <p class="extra_spacing_top">Age ≥1 year:</p> <ul class="decimal_heading"> <li>&lt;20 kg: 10 mg orally 3 times per day</li> <li>≥20 kg: 20 mg orally 3 times per day</li> </ul> <p class="extra_spacing_top">Maximum dose:</p> <ul class="decimal_heading"> <li>20 mg orally 3 times per day</li> </ul> </td> <td>Headache, flushing, nasal congestion, epistaxis, dizziness, hypotension, peripheral edema, dyspepsia, diarrhea, priapism</td> <td> <ul> <li>Co-administration of nitrates is contraindicated</li> <li>Sensorineural hearing loss and ischemic optic neuropathy have been reported</li> <li>In extremely preterm infants, use should be delayed until retinal vascularization established</li> </ul> </td> </tr> <tr> <td class="indent1">Tadalafil</td> <td>Adcirca</td> <td> Initial dose: <ul class="decimal_heading"> <li>1 mg/kg/dose orally once daily</li> </ul> <p class="extra_spacing_top">Maximum dose:</p> <ul class="decimal_heading"> <li>40 mg/day</li> </ul> </td> <td>Similar to sildenafil</td> <td> <ul> <li>Co-administration of nitrates is contraindicated</li> <li>Sensorineural hearing loss has been reported</li> <li>Ischemic optic neuropathy has been reported</li> <li>Very limited information in children regarding dosing, safety, and efficacy</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Calcium channel blockers*</td> </tr> <tr> <td class="indent1">Nifedipine</td> <td> </td> <td> Initial dose: <ul class="decimal_heading"> <li>0.1 to 0.2 mg/kg per dose orally 3 times per day; increase to 2 to 3 mg/kg/day total oral dose</li> </ul> <p class="extra_spacing_top">Maximum dose:</p> <ul class="decimal_heading"> <li>180 mg/day</li> </ul> <p class="extra_spacing_top">Extended release tablets preferred for patients able to swallow whole pills</p> </td> <td>Hypotension, bradycardia, flushing, headache, peripheral edema, dizziness, rash, gingival hyperplasia</td> <td> <ul> <li>Contraindicated with RV dysfunction</li> <li>Used in patients who demonstrate a response to AVT</li> </ul> </td> </tr> <tr> <td class="indent1">Amlodipine</td> <td> </td> <td> Initial dose: <ul class="decimal_heading"> <li>0.1 to 0.3 mg/kg per dose orally once daily; may increase to 2.5 to 10 mg orally once daily</li> </ul> <p class="extra_spacing_top">Maximum dose:</p> <ul class="decimal_heading"> <li>10 mg/day</li> </ul> </td> <td>Similar to nifedipine</td> <td> <ul> <li>Contraindicated with RV dysfunction</li> <li>Used in patients who demonstrate a response to AVT</li> </ul> </td> </tr> <tr> <td class="indent1">Diltiazem</td> <td> </td> <td> Initial dose: <ul class="decimal_heading"> <li>0.5 mg/kg/dose orally 3 times per day; increase to 2 to 5 mg/kg/day total oral dose</li> </ul> <p class="extra_spacing_top">Maximum dose:</p> <ul class="decimal_heading"> <li>360 mg/day</li> </ul> <p class="extra_spacing_top">Extended release formulations preferred for patients able to swallow whole pills</p> </td> <td>Similar to nifedipine</td> <td> <ul> <li>Contraindicated with RV dysfunction</li> <li>Used in patients who demonstrate a response to AVT</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Endothelin receptor antagonists</td> </tr> <tr> <td class="indent1">Bosentan</td> <td>Tracleer</td> <td> <p>Starting dose is one-half maintenance dose; increase to full maintenance after 2 to 4 weeks if LFTs and Hgb are stable</p> Maintenance dose: <ul class="decimal_heading"> <li>&lt;10 kg: 2 mg/kg/dose orally twice per day</li> <li>10 to 20 kg: 31.25 mg orally twice per day</li> <li>20 to 40 kg: 62.5 mg orally twice per day</li> <li>&gt;40 kg: 125 mg orally twice per day</li> </ul> <p class="extra_spacing_top">Maximum dose:</p> <ul class="decimal_heading"> <li>125 mg orally twice per day</li> </ul> </td> <td> <p>Abdominal pain, vomiting, extremity pain, fatigue, flushing, headache, edema, nasal congestion, anemia, decreased sperm count</p> Potential risk of dose-dependent increases in aminotransaminase levels</td> <td> <ul> <li>Monitor LFTs and Hgb and adjust dose per manufacturer's recommendations</li> <li>Not recommended in patients with moderate or severe hepatic impairment</li> <li>Caution with concomitant use of CYP3A4 inducers and inhibitors</li> <li>Is a teratogen; pregnancy test required prior to use and for 1 month afterwards; 2 forms of contraception required</li> <li>Concurrent use of bosentan and sildenafil increases bosentan serum levels and decreases sildenafil levels</li> </ul> </td> </tr> <tr> <td class="indent1">Ambrisentan</td> <td>Letairis</td> <td> Maintenance dose: <ul class="decimal_heading"> <li>&lt;20 kg: 2.5 to 5 mg orally once daily</li> <li>&gt;20 kg: 5 to 10 mg orally once daily</li> </ul> <p class="extra_spacing_top">Maximum dose:</p> <ul class="decimal_heading"> <li>10 mg/day</li> </ul> </td> <td> <p>Peripheral edema, nasal congestion, headache, flushing, anemia, nausea, and decreased sperm count</p> The incidence of serum aminotransferase elevation is low</td> <td> <ul> <li>Obtain baseline LFTs and Hgb, monitor after 1 month, then every 6 months or as clinically indicated</li> <li>Teratogenicity concerns as for bosentan</li> <li>Little efficacy and safety data for children; avoid use in neonates and infants</li> </ul> </td> </tr> <tr> <td class="indent1">Macitentan</td> <td>Opsumit</td> <td> <p>Pediatric dosing is not established</p> Adult dosing: <ul class="decimal_heading"> <li>10 mg orally daily</li> </ul> </td> <td> <p>Nasal congestion, headache, flushing, anemia, decreased sperm count</p> The incidence of serum aminotransferase elevation is low</td> <td> <ul> <li>Obtain baseline LFTs and Hgb and monitor as clinically indicated</li> <li>Teratogenicity as for other ERAs</li> <li>Infrequently used in children as there are no available data in pediatric patients</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Prostacyclin analogues</td> </tr> <tr> <td class="indent1">Epoprostenol (IV)</td> <td> <p>Flolan</p> Veletri</td> <td> Initial infusion rate: <ul class="decimal_heading"> <li>1 to 3 nanograms/kg/min; slowly increase infusion rate over weeks</li> </ul> <p class="extra_spacing_top">Maintenance infusion rate:</p> <ul class="decimal_heading"> <li>50 to 80 nanograms/kg/min, titrated to effect</li> </ul> <p class="extra_spacing_top">No clear maximum dose</p> </td> <td>Flushing, headache, nausea, diarrhea, jaw discomfort, rash, hypotension, thrombocytopenia</td> <td> <ul> <li>Potential risk of hypotension and bleeding in children receiving concomitant drugs such as anticoagulants, platelet inhibitors, or other vasodilators</li> <li>Bolus infusion can cause systemic hypotension</li> <li>Short elimination half-life (3 to 5 minutes); PH crises can occur rapidly if infusion is stopped</li> <li>Cooling is needed for Flolan but not Veletri</li> <li>Dose increases needed due to tachyphylaxis</li> </ul> </td> </tr> <tr> <td class="indent1">Iloprost (inhaled)</td> <td>Ventavis</td> <td> Initial dose: <ul class="decimal_heading"> <li>2.5 micrograms per inhalation 6 times a day</li> </ul> <p class="extra_spacing_top">Maintenance dose:</p> <ul class="decimal_heading"> <li>5 micrograms per inhalation 6 to 9 times per day</li> </ul> <p class="extra_spacing_top">Maximum dose:</p> <ul class="decimal_heading"> <li>45 mcg/day</li> </ul> </td> <td>Cough, wheeze, headache, flushing, jaw pain, diarrhea, rash, hypotension (at higher doses)</td> <td> <ul> <li>Elimination half-life 20 to 30 minutes</li> <li>Potential risk of exacerbating reactive airway disease symptoms</li> <li>Patient must be old enough to initiate breath from nebulizer</li> </ul> </td> </tr> <tr> <td class="indent1">Treprostinil (IV/SC)</td> <td>Remodulin</td> <td>As for epoprostenol, but maintenance infusion rate may need to be higher</td> <td> <p>As for epoprostenol</p> Pain and redness at SC infusion site</td> <td> <ul> <li>Stable at room temperature</li> <li>Elimination half-life 4 hours</li> </ul> </td> </tr> <tr> <td class="indent1">Treprostinil (inhaled)</td> <td>Tyvaso</td> <td> Initial dose: <ul class="decimal_heading"> <li>3 breaths (18 micrograms) 4 times a day</li> </ul> <p class="extra_spacing_top">Maintenance dose:</p> <ul class="decimal_heading"> <li>9 breaths (54 micrograms) 4 times a day</li> </ul> </td> <td>Cough, headache, nausea, dizziness, flushing, throat irritation</td> <td> <ul> <li>As for iloprost</li> <li>Elimination half-life 4 hours</li> <li>Potential risk of exacerbating reactive airway disease symptoms</li> </ul> </td> </tr> <tr> <td class="indent1">Treprostinil diolamine (oral)</td> <td>Orenitram</td> <td> Initial dose: <ul class="decimal_heading"> <li>0.125 to 3 times per day, <strong>or</strong></li> <li>0.25 mg orally twice per day</li> </ul> <p class="extra_spacing_top">Maintenance dose:</p> <ul class="decimal_heading"> <li>Determined by tolerability</li> </ul> </td> <td>Headache, nausea, diarrhea, jaw pain, extremity pain, hypokalemia, abdominal discomfort, flushing</td> <td> <ul> <li>Must be taken with food</li> <li>Limited experience in pediatric patients</li> <li>Unlikely to be sufficient substitute for parenteral prostacyclin for patients requiring high-dose prostacyclin</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes medications used in the management of pediatric PH. Data on the efficacy, dosing, and safety of these agents in children are limited. Most of these agents (with the exception of sildenafil) are not specifically approved by the FDA or EMA for treatment of pediatric PH. Infants and children with PH should be managed in centers with the experience, special expertise, and multidisciplinary teams necessary to provide care for these patients. For additional details, refer to UpToDate topics on PH in children.</div><div class="graphic_footnotes"><p>PDE5: phosphodiesterase type 5; RV: right ventricle; AVT: acute vasoreactivity testing; LFT: liver function test; Hgb: hemoglobin; CYP3A4: cytochrome P450 3A4; ERA: endothelin receptor antagonist; IV: intravenous; PH: pulmonary hypertension; SC: subcutaneous; FDA: Food and Drug Administration; EMA: European Medicines Agency.</p>
    
    * Calcium channel blockers play a limited role in management of pediatric PH. They are used selectively in patients who have vasoreactivity documented on cardiac catheterization. Refer to UpToDate topics on PH in children for details.</div><div class="graphic_reference">Adapted from: Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: Guidelines from the American Heart Association and American Thoracic Society. Circulation 2015; 132:2037.</div><div id="graphicVersion">Graphic 114507 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
